← Leaderboards
Kathleen E. Squires
University Of Southern California
$5,307,612
Attributed
$5,307,612
Total exposure
12
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $955.7K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$5,307,612 · 12
By mechanism
U01$5,016,163 · 2
M01$291,449 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Alice Stek$1,651,428
- Michael G Dube$1,076,796
- Fred R Sattler$24,195,984
- Andrea A. Kovacs$11,647,115
- Debra Johnson$0
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHiv InfectionsResearch PersonnelRitonavirHuman SubjectAids TherapyHuman Therapy EvaluationProtease InhibitorResourcesBasePharmaceutical PreparationsPharmacokineticsLopinavir/RitonavirRandomizedSourceGrantFundingEfavirenzComputer Retrieval Of Information On Scientific Projects DatabasePatient Oriented ResearchUnited States National Institutes Of HealthInstitutionProdrugsLamivudine
Grant awards (17)
Quintiles Clinical Trial Unit for HIV/AIDS Clinical Trials Networks$886,623
U01 · FY2009 · AI · contact PI
Quintiles Clinical Trial Unit for HIV/AIDS Clinical Trials Networks$946,844
U01 · FY2008 · AI · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS$8,292
M01 · FY2008 · RR · contact PI
DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN$552
M01 · FY2008 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS$51,576
M01 · FY2007 · RR · contact PI
DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN$3,435
M01 · FY2007 · RR · contact PI
DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN$6,060
M01 · FY2006 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LIPONAVIR/RITONAVIR PLUS$105,412
M01 · FY2005 · RR
ACTG A5039: AN OPEN-LABEL, NON-RANDOMIZED STUDY OF PHARMACOKINETIC INTERACTIONS$21,511
M01 · FY2005 · RR
A PHASE II STUDY OF THE PREDICTIVE VALUE OF PHARMACOKINETIC-ADJUSTED PHENOTYPIC$17,213
M01 · FY2005 · RR
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY,$2,149
M01 · FY2005 · RR
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON$34,396
M01 · FY2004 · RR
ACTG A5039: AN OPEN-LABEL, NON-RANDOMIZED STUDY$19,349
M01 · FY2004 · RR
A RANDOMIZED, COMPARATIVE STUDY OF LIPONAVIR/RITONAVIR$10,752
M01 · FY2004 · RR
A PHASE II STUDY OF PREDICTIVE VALUE OF PHARMACOKINETICS$10,752
M01 · FY2004 · RR
ADULT AIDS CLINICAL TRIALS UNIT (ACTU)$1,639,776
U01 · FY2003 · AI
ADULT AIDS CLINICAL TRIALS UNIT (ACTU)$1,542,920
U01 · FY2002 · AI